Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (NASDAQ: SMMT).

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...

Joel Beatty; Analyst; Robert W. Baird & Co. Incorporated ...

February 10, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, both ...

Companies that pay dividends have been a reliable choice for investors seeking a passive and somewhat stable income.

H.C. Wainwright downgraded Pliant Therapeutics (PLRX) to Neutral from Buy without a price target after the company voluntarily paused ...

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Hello, everyone, and welcome to the Iterum Therapeutics PLC Fourth-Quarter and Full Year 2024 Financial Results. My name is Ezra, and I will be your coordinator today. (Operator Instructions) I will ...

Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.